EEG-Based Brain-Computer Interface Project for Individuals With Amyotrophic Lateral Sclerosis (ALS)
NCT00718458 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 102
Last updated 2017-03-30
Summary
Amyotrophic lateral sclerosis (ALS) is a progressive neuromuscular condition characterized by weakness, muscle wasting, fasciculations and increased reflexes. Depending on the site of onset, individuals with ALS progressively lose control of their skeletal muscles; bulbar or the extremities. As symptoms worsen and spread, muscle atrophy becomes apparent and upper motor neuron symptoms such as spasticity complicate gait (in lower limb involvement) and manual dexterity (in upper limb involvement). The patients progress to a state of profound disability and have great difficulty in communicating; some may even be entirely "locked in" to their bodies. The capacity for simple communication could greatly improve their quality of life.
New technologies are giving people with disabilities alternate communication and control options. One such instrument is the EEG-based Brain-Computer Interface (BCI) which can provide both communication and control functions to those who have lost muscle control. By recording electroencephalographic (EEG) signals or brain waves from the scalp and then decoding them, the Wadsworth BCI allows people to make selections on a computer screen \[i\] In this study we will be investigating the feasibility of using EEG-based Brain-Computer Interface technology as a communication solution for individuals with ALS. The specific question addressed will be: Can individuals with ALS use the BCI for communication when they present with extreme loss of neuromuscular control and severe communication impairments? The goal of the project is to determine whether this device is a practical and realistic means for individuals with ALS to communicate. The study is intended to evaluate both the complexity of the system and the degree to which each participant will be able to communicate. Trials will consist of asking the subject to follow a series of simple instructions and complete certain tasks while using the BCI.
This study design requires that the individual live in the Philadelphia region. Please contact the Wadsworth Center of the New York State Department of Health and State University of New York at Albany directly if you reside outside of this area.
Conditions
- Amyotrophic Lateral Sclerosis
- Neurodegenerative Disease
- Motor Neuron Disease
Sponsors & Collaborators
-
MDA/ALS Center of Hope
collaborator OTHER -
Drexel University College of Medicine
lead OTHER
Principal Investigators
-
Terry Heiman-Patterson, MD · MDA/ALS Center of Hope
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2007-08-31
- Primary Completion
- 2016-12-31
- Completion
- 2016-12-31
Countries
- United States
Study Locations
More Related Trials
-
Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis
NCT02559869 ·Status: COMPLETED
-
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
NCT02327845 ·Status: ENROLLING_BY_INVITATION
-
Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program
NCT00716131 ·Status: COMPLETED
-
Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS)
NCT02000713 ·Status: TERMINATED ·Phase: NA
-
Comprehensive Biomarker Profiling of the IFN-α Pathway in Amyotrophic Lateral Sclerosis Patient Biofluids
NCT07260981 ·Status: COMPLETED
-
Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)
NCT00677768 ·Status: COMPLETED
-
Amyotrophic Lateral Sclerosis: A Multicenter Retrospective Observational Registry
NCT07143656 ·Status: ACTIVE_NOT_RECRUITING
-
Contralateral R1 in Amyotrophic Lateral Sclerosis
NCT06206629 ·Status: COMPLETED
-
Biomarker-driven Phenotypic Dissection of Amyotrophic Lateral Sclerosis
NCT06318598 ·Status: RECRUITING
-
Circulating Biomarker for Amyotrophic Lateral Sclerosis (ALS)
NCT03088839 ·Status: UNKNOWN
-
Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation
NCT02794857 ·Status: COMPLETED ·Phase: PHASE2
-
Amyotrophic Lateral Sclerosis and the Innate Immune System
NCT02869048 ·Status: RECRUITING
-
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
NCT02611674 ·Status: COMPLETED
-
Amyotrophic Lateral Sclerosis (ALS) Families Project
NCT03865420 ·Status: RECRUITING
-
Neuromuscular Magnetic Stimulation in ALS Patients
NCT03618966 ·Status: COMPLETED ·Phase: PHASE2
-
Digital Assessment of Speech and Fine Motor Control in ALS
NCT06315673 ·Status: RECRUITING
-
Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis
NCT02447952 ·Status: COMPLETED ·Phase: NA
-
PREVENT ALL ALS Study
NCT06581861 ·Status: RECRUITING
-
Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients
NCT02424669 ·Status: UNKNOWN ·Phase: NA
-
Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis
NCT02969759 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Determinants of Disease Severity in Amyotrophic Lateral Sclerosis
NCT00004457 ·Status: UNKNOWN
-
ALS Research Collaborative
NCT06885918 ·Status: RECRUITING
-
A Study of the Expression of Nogo and Reticulon Genes in Skeletal Muscle of Patients With Amyotrophic Lateral Sclerosis
NCT00213824 ·Status: TERMINATED
-
Validation of a New Device to Measure Neuromuscular Disease Progression
NCT00606918 ·Status: COMPLETED
-
Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis
NCT01992029 ·Status: TERMINATED